Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Mr. Jose Ignacio Abia est le Chief Executive Officer de Grifols, S.A., il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action Grifols, S.A. ?
Le prix actuel de Grifols, S.A. est de $7.96, il a diminué de 1.03% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Grifols, S.A. ?
Grifols, S.A. appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Grifols, S.A. ?
La capitalisation boursière actuelle de Grifols, S.A. est de $2.0B
Est-ce que Grifols, S.A. est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 18 analystes ont établi des notations d'analystes pour Grifols, S.A., y compris 3 achat fort, 10 achat, 4 maintien, 2 vente et 3 vente forte